Cell Medica starts commercial cell therapy manufacture in Germany

19 February 2015

UK-based cellular immunotherapy company Cell Medica has announced the start of commercial cell therapy manufacturing at its facility at the Max-Delbrück-Center of Molecular Medicine in Berlin-Buch, Germany.

The portfolio company of Imperial Innovations Group (AIM: IVO) said that the first product has been successfully manufactured and delivered for use. Manufacturing at this site will initially be focused on Cytovir CMV for the treatment of patients with cytomegalovirus (CMV) infections following a hematopoietic stem cell (bone marrow) transplant.

Cytovir CMV is an individualized immune cell therapy that is comprised of naturally-occurring donor cytotoxic T cells which are transferred from a donor into an immunosuppressed patient, in order to reconstitute their immunity to Cytomegalovirus (CMV). The product is currently available to treat patients in the UK, Ireland and Germany.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK